As per this study the Global Non-Hodgkin Lymphoma Therapeutics Market was valued USD 4.8 BN (by revenue) in 2017 and is anticipated to reach USD 7.7 BN by 2024 with a CAGR of 7%.
 
Non-hodgkin lymphoma is the type of blood cancer that affects the lymphatic system. The infected cells lose their ability to fight infection, thus the make body vulnerable to other infections. Radiation therapy, chemotherapy and others are the therapeutics used to treat blood cancers.
 
Objectives of the Study:

• Define and measure the global non-hodgkin lymphoma therapeutics market
• Revenue forecast of the global non-hodgkin lymphoma therapeutics market and its various sub-segments with respect to main geographies
• Analyze and identify major market trends along with the factors driving or inhibiting the market growth
• Study the company profiles of the major market players with their market share
• Analyze competitive developments

 
Market Dynamics
 
Rising prevalence of cancer across the globe and increasing demand of monoclonal antibodies and novel therapies to treat cancer is driving the market growth. Increased R&D for development of novel therapies is further boosting the market growth. However, high cost of drugs is likely to restrain the market growth in following years.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of non-hodgkin lymphoma therapeutics.
 
Market Segmentation
 
The broad non-hodgkin lymphoma therapeutics market has been sub-grouped into cancer type and therapeutics. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
 
By Cancer Type

• Glioma
• Meningioma
• Pituitary Adenoma
• Schwannomas
• Medulloblastoma

 
By Therapeutics

• Radiation Therapy
• Chemotherapy
• Targeted Therapy

 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for non-hodgkin lymphoma therapeutics in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Europe Non-Hodgkin Lymphoma Therapeutics Market By Revenue (USD MN)
 

 
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Bayer AG, Bristol Myers Squibb Co., F. Hoffman La-Roche Ltd., GlaxoSmithKline plc, Merck, Novartis, Pfizer, and others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.